Company intelligence / Profile preview

Algeta ASA

Ownership: Private
Employees: ~180
Development stage: Commercial

Overview

Algeta's lead product Xofigo (radium Ra 223 dichloride) was approved by the FDA in May 2013 and by the European Medicines Agency in November 2013 for treating castration-resistant prostate cancer with symptomatic bone metastases. In clinical trials, Xofigo showed improved overall survival of 14 months compared to 11.2 months in the placebo group[1].

Therapeutic areas: Oncology
Modalities: Alpha-particle emitting radiopharmaceuticals
Industry: Biotech

Drug pipeline

1 asset

radium-223 dichloride

Commercial

Indications: Castration-resistant prostate cancer, Prostate cancer with bone metastases

Partnerships

Bayer AG

Beyond the preview

Go deeper on Algeta ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algeta ASA.

Explore the full profile